bullous pemphigoid

The FDA has opened the investigational new drug application for Phase 3 trial for Akari Therapeutics Plc's (NASDAQ: AKTX) lead drug candidate, nomacopan, for the treatment of moderate and severe Bullous Pemphigoid (BP), allowing clinical sites to open mid-2021, subject...